AT&TSample data
AT&T · Employer portal

Financial Impact & Opportunity

Consolidated CFO view: investment, validated value, payback and performance metrics.

Medical Offsets
41.4% of total
$15.3M

Modeled reductions in medical expenditures associated with improved employee health outcomes.

· 2.2% utilization reduction per member/year
· $75 estimated savings per member/year
View Medical Offset Breakdown
Workforce Value
58.6% of total
$21.7M

Modeled employer value associated with workforce productivity, attendance, and employee engagement.

· Cost avoidance: $5.25M (OT + temp labor)
· Productivity value: $6.16M (recovered + on-the-job)
View Workforce Value Breakdown
GLP-1 drug spending
$8.11M
18,024 member-months
Observed
Program fee
$10.80M
$5,400 / member
Observed
Combined cost
$18.91M
before adjustments
Observed

10-Year Economic Outlook

Sample data

Drag any point to reshape a curve. Hover any month for detailed values and the economic value breakdown. Crossover years recompute automatically.

Illustrative Financial Model — Subject to Assumptions and Validation
$0M$15M$30M$45M12345678910Program year
Medical Costs
Medical Offsets
Workforce Value
Workforce value crosses medical costs
≈ Year 4.3
Medical offsets cross medical costs
≈ Year 6.7
Medical offsets cross workforce value
Not within 10 years
10-Year Annual Averages
Medical Offsets
$10.0M
Workforce Value
$17.0M
Medical Costs
$18.4M

Approved executive display figures. Calculated arithmetic averages of the supplied annual data match these targets — no reconciliation gap.

Modeled Employer Value
Year 10 · Month 12
$37.0M
Medical Offsets
$15.3M
41.4% of total
Workforce Value
$21.7M
58.6% of total

Illustrative allocation of modeled employer value. Medical offsets reflect a demonstration allocation and are not derived from the underlying PayRX medical utilization model.

Three annual series: Medical Costs (declining), Medical Offsets (increasing), Workforce Value (increasing). 10-year annual averages: Medical Offsets $10.0M, Workforce Value $17.0M, Medical Costs $18.4M. All figures illustrative.

Workforce Value Breakdown

Cost Avoidance and Productivity Value are distinct categories. Combined total represents estimated economic value, not realized cash savings.

Cost AvoidanceModeled
Overtime costs avoided$3.40M
Temp / relief labor avoided$1.84M
Total cost avoidance$5.25M
Productivity ValueModeled
Uncovered work recovered$851K
On-the-job productivity value$5.30M
Total productivity value$6.16M

Productivity value remains modeled in both views. Manager submissions cover cost avoidance only.

Combined Modeled Financial Impact· over 12 months
$11.40M
CA 46%
PV 54%
Cost Avoidance: $5.25M (46.0%)Productivity Value: $6.16M (54.0%)
Overtime costs avoided
$3.40M
Temp / relief labor avoided
$1.84M
Uncovered work recovered
$851K
On-the-job productivity value
$5.30M
Avoided medical costs (separate, not in combined total)Modeled
$3.42M
Validation status detailTap status to toggle modeled line items
Overtime costs avoided$3.40M
Temp / relief labor avoided$1.84M
Uncovered work recovered$851K
On-the-job productivity value$5.30M
Avoided medical costs$3.42M

All items are modeled. Toggle simulates which values Finance has confirmed. See Manager Data & Validation for employer-reported inputs.

Adjustable program fees

$5,400
25%
Performance-based fee adjustment
Total program fee$10.80M
Fee at risk$2.70M25%
Targets4 of 5 met
Adjustment−$540K1 unmet
Adjusted fee$10.26M95% of original

Whether the adjustment is a credit, refund or withheld payment depends on the agreement.

Financing scenarios

Counted investment
Program fee$10.80Mover 12 months
Total investment$10.80M
Financial perspective
Net value (Budget dollars)
−$5.55M
Validated value minus counted investment
Save this scenario

Save the current assumptions as a named scenario for side-by-side comparison.

Financial performance metrics

Illustrative · Year 1
EPS Attributable to Program Expenses — Year 1
Without PayRX
−$0.0303
per diluted share
With PayRX
−$0.0075
per diluted share
EPS Protected
+$0.0228
per diluted share
Pre-tax Earnings Equivalent
~$211.2M
EPS protected × 6.946B shares ÷ (1 − 25%)
Equity Valuation Sensitivity
~$1.58B
EPS protected × shares × 10× P/E · illustrative

Based on 6.946 billion diluted shares. Reconciliation: −$0.0075 − (−$0.0303) = +$0.0228. Illustrative EPS impact attributable to program expenses, not AT&T's total reported EPS. Do not label as guaranteed earnings growth.

EBITDA impact
Without PayRx
−$34.56M
pretax
With PayRx
−$10.02M
pretax
Protected
+$24.54M
difference

Reconciliation: −$10.02M − (−$34.56M) = +$24.54M. Pre-tax EBITDA impact, distinct from after-tax EPS. Diluted shares (6.946B) and tax rate (25%) apply to EPS reconciliation only, not to EBITDA.

·

All figures illustrative · synthetic data · not validated financial results

Employee Privacy Protected by Design

Employer reporting is designed to present aggregate workforce and health-program insights without exposing individual clinical records. Small-group reporting restrictions help reduce the risk of employee identification.

Sample dataPrivacy-restricted reporting

Aggregated information is not described as HIPAA-de-identified unless applicable de-identification requirements have been satisfied and verified.

Sample Data — Demonstration Only. Fictional data, not actual patient records or validated outcomes.